Eli Lilly (LLY +2.6%) pops after a new study shows its experimental Alzheimer’s treatment slowed...

Eli Lilly (LLY +2.6%) pops after a new study shows its experimental Alzheimer’s treatment slowed memory loss and cognitive decline in early-stage patients by ~30%, offering the first evidence that a medication may hamper the course of the ailment. The independent study supports LLY’s August report that showed the drug, solanezumab, slowed mental decline in those with mild Alzheimer’s.

From other sites
Comments (1)
  • WealthParadox
    , contributor
    Comments (22) | Send Message
    Just to be clear
    LLY claims that disease progressions were slowed
    • Using a 11-variable test: 42% in mild patients in EXP 1 cohort with pvalue = 0.008 (significant)
    • Using a 14-variable test: 20% in mild patients in EXP 2 cohort with pvalue = 0.12 (not significant)
    • Using a 14-variable test: 34% in mild patients in EXP 1+2 cohorts with pvalue = 0.001 (significant)


    The improvement in ADAS COGS was less than 2 pts, while functional improvement not statistically significant in any pool. Also, the company decided to prolong the agony by not publishing the biomarker data until 10/29 CTAD meeting in Monaco. If you're an investor listen to the call tonight and ask yourself: "Do I believe?" Because this company requires faith.
    8 Oct 2012, 03:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs